If there is one strong message Camille Hertzka, AstraZeneca vice president and head of oncology, U.S. medical, wants people to take away from lung cancer …
Is autoinflammatory disease treatment Ilaris a potential new therapy for non-small cell lung cancer (NSCLC)? After two pivotal trial failures, the answer seems to be …
Roche’s Tecentriq has ushered in a new era, offering the first immunotherapy option for non-small cell lung cancer (NSCLC) patients right after tumour surgery. But …
AstraZeneca has signed a deal with US group G1 Therapeutics to test the potential of a new combination therapy for lung cancer. The parties have …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
